SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on June 5, 2020, covering events occurring on June 4 and June 5, 2020. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational and scientific milestones rather than financial performance data.
Material Changes and Operational Updates
- Scientific Acceptance: Two scientific sessions highlighting the Company's PURE EP(tm) System were accepted into the Heart Rhythm Society 2020 Science.
- Subsidiary Expansion: ViralClear Pharmaceuticals, Inc., a majority-owned subsidiary, expanded its patient enrollment centers to include St. David's South Austin Medical Center in Austin.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the operational announcements. The report serves to disclose these specific events as required under Item 8.01 (Other Events).
Key Facts for Investor Verification
- Verify the details of the PURE EP(tm) System sessions accepted by the Heart Rhythm Society via the press release filed as Exhibit 99.1.
- Confirm the operational status and enrollment capacity of the new ViralClear center at St. David's South Austin Medical Center via Exhibit 99.2.
- Note that the company name in the metadata request ("Streamex Corp.") differs from the registrant name in the filing ("BioSig Technologies, Inc."); the summary reflects the actual filing content.